IP Library › Patent Application 14963190
Patent Application
App. No. 14/963,190

c-Met Antibody Drug Conjugate

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/963,190
Abstract

There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.

Claims (8)

1 . An antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety.

2 . The ADC composition of claim 1 , wherein the toxin moiety is a tubulin inhibitor or a doxorubicin analog.

3 . The ADC composition of claim 1 , wherein the antibody is an IgG antibody from the H8 (heavy/light SEQ ID NOs 19/20) family or is a B12 (heavy/light SEQ ID NOs 7/8), wherein the H8 antibody family is selected from the group consisting of H8-A2, H8-9, H8-9EE8L3, H8-C1, H8-D4, H8-D5, H8-D6, H8-D10, H8-E5, H8-G7, H8-H6, H8-2A2, H8-2B1, H8-2B2, H8-2B4, H8-2B7, H8-A7P, H8-9EH11L, H8-9EH11L, and H8-6AG2H3.

4 . The ADC composition of claim 1 , wherein the conjugated toxin is

5 . A method for treating breast cancer, comprising administering an effective amount of an antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety.

6 . The method for treating breast cancer of claim 5 , wherein the toxin moiety is a tubulin inhibitor or a doxorubicin analog.

7 . The method for treating breast cancer of claim 5 , wherein the antibody is an IgG antibody from the H8 (heavy/light SEQ ID NOs 19/20) family or is a B12 (heavy/light SEQ ID NOs 7/8), wherein the H8 antibody family is selected from the group consisting of H8-A2, H8-9, H8-9EE8L3, H8-C1, H8-D4, H8-D5, H8-D6, H8-D10, H8-E5, H8-G7, H8-H6, H8-2A2, H8-2B1, H8-2B2, H8-2B4, H8-2B7, H8-A7P, H8-9EH11L, H8-9EH11L, and H8-6AG2H3.

8 . The method for treating breast cancer of claim 5 , wherein the conjugated toxin is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2016
From: ZHU, TONG; CHEN, GANG; FU, YANWEN; GROS, EDWIGE
To: SORRENTO THERAPEUTICS INC.
Reel/Frame 037425/0318 →